Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Evaluate the PD profile of BN83495 after 28 days of daily oral administration in patients with locally advanced or metastatic prostate cancer on androgen ablative therapy and with rising prostatic specific antigen
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Confirmed and locally advanced or metastatic prostate cancer with rising prostate-specific antigen (PSA), while on androgen ablative therapy.
Over age 18.
Demonstrated PSA "biochemical failure".
Adequate bone marrow and hepatic function
You may not be if
Luteinizing Hormone-Releasing Hormone analogue treatment and treated with more than one additional second line of endocrine therapy
Prior treatment with ketoconazole
Prior chemotherapy for hormone refractory prostate cancer
Pre-existing cardiac failure and/or clinically significant abnormal ECG or Echo
